Résultats de la recherche
10
Tout
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
05 nov. 2024 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Hofstra North Shore-LIJ School of Medicine Professor Publishes Pivotal MS Study
08 août 2014 13h17 HE
|
North Shore Long Island Jewish Health System
HEMPSTEAD, N.Y., Aug. 8, 2014 (GLOBE NEWSWIRE) -- A Hofstra North Shore-LIJ School of Medicine professor has published breakthrough research that pinpoints the origin of the cell that is alleged to...